Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Treasury Shares (2016 - 2025)

Vanda Pharmaceuticals' Treasury Shares history spans 17 years, with the latest figure at $3.5 million for Q4 2025.

  • On a quarterly basis, Treasury Shares rose 31.19% to $3.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $3.5 million, a 31.19% increase, with the full-year FY2025 number at $3.5 million, up 31.19% from a year prior.
  • Treasury Shares hit $3.5 million in Q4 2025 for Vanda Pharmaceuticals, roughly flat from $3.5 million in the prior quarter.
  • Over the last five years, Treasury Shares for VNDA hit a ceiling of $3.5 million in Q2 2025 and a floor of $1.8 million in Q4 2021.
  • Historically, Treasury Shares has averaged $2.4 million across 5 years, with a median of $2.0 million in 2022.
  • Biggest five-year swings in Treasury Shares: dropped 2.33% in 2023 and later skyrocketed 42.05% in 2024.
  • Tracing VNDA's Treasury Shares over 5 years: stood at $1.8 million in 2021, then grew by 8.55% to $1.9 million in 2022, then decreased by 0.53% to $1.9 million in 2023, then surged by 39.09% to $2.7 million in 2024, then soared by 31.19% to $3.5 million in 2025.
  • Business Quant data shows Treasury Shares for VNDA at $3.5 million in Q4 2025, $3.5 million in Q3 2025, and $3.5 million in Q2 2025.